R&D Systems Inc. Tocris Bioscience Boston Biochem

Ozagrel hydrochloride

Cat. No. 1510

Ozagrel hydrochloride C13H12N2O2.HCl [74003-18-2]

Price and Availability

For Ozagrel hydrochloride pricing & availability please select your country from the drop down menu:
Submit
By clicking submit you agree to accept a cookie from Tocris Bioscience. For details, please read our privacy and cookie policy.

Alternative Name: OKY 046

Chemical Name: (2E)-3-[4-(1H-Imidazol-1-ylmethyl)phenyl]-2-propenoic acid hydrochloride

Biological Activity

Potent and selective inhibitor of thromboxane (TXA2) synthetase (IC50 = 4 nM). Does not inhibit prostacyclin (PGI2) synthetase, cyclooxygenase or PGE2 isomerase (IC50 > 1 mM). Inhibits platelet aggregation in vitro and arachidonate-induced arterial contraction in vivo.

Technical Data

M.Wt:
264.71
Formula:
C13H12N2O2.HCl
Solubility:
Soluble to 100 mM in water
Purity:
>98 %
Storage:
Store at RT
CAS No:
74003-18-2

The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.

Certificate of Analysis / Safety Data Sheet

Certificate of Analysis: View current batch
Select another batch:
Safety Data Sheet: View Safety Data Sheet

References

Naito et al (1983) Effects of thromboxane synthetase inhibitors on aggregation of rabbit platelets. Eur.J.Pharmacol. 91 41. PMID: 6413227.

Hiraku et al (1986) Pharmacological studies on the TXA2 synthetase inhibitor (E)-3-[p-(1H-imidazol-1ylmethyl)phenyl]-2-propenoic acid (OKY-046). Jpn.J.Pharmacol. 41 393. PMID: 3093741.

Shinagawa et al (2000) Participation of thromboxane A2 in the cough response in guinea-pigs: antitussive effect of ozagrel. Br.J.Pharmacol. 131 266. PMID: 10991919.

If you know of a relevant citation for this product please let us know.

Keywords: Ozagrel hydrochloride, supplier, Selective, thromboxane, A2, synthetase, inhibitors, Thromboxane, TP, Prostanoid, Synthases, Synthetases, prostaglandins, prostacyclins, eicosanoids, OKY046

Quick Order

Find multiple products by catalog number

divider line

Immunology Guide

Immunology Research Guide

Highlights over 150 products for immunology research. Request a copy or view PDF today.

divider line

New Therapies and Challenges in Asthma

Written by Peter J. Barnes

Asthma Poster

'New Therapies, Challenges, and Breakthroughs in Asthma' highlights key pathways and new therapies used to treat asthma, including those currently in clinical development.

divider line

Peripheral Sensitization

Written by Grant D. Nicol and Michael R. Vasko

Pain Poster

A summary of the excitatory and inhibitory signaling pathways involved in modulation of peripheral sensitization. Request a copy or view PDF today.

divider line

Regulation of Vascular Reactivity by GPCRs

Written by J.J. Maguire and A.P. Davenport

Cardiovascular Poster

'Regulation of Vascular Reactivity by G-protein-coupled Receptors' summarizes the key GPCRs regulating vascular reactivity.

divider line

7-TM Receptor Signaling

Written by T. Kenakin et al

7-TM Poster

'Seven Transmembrane Receptor Signaling' highlights the multiple behaviors of 7-TMs including G-protein-dependent and -independent signaling as well as the concept of collateral efficacy

divider line

New Product Guide

NPG

Highlights 140 new products added in the first half of 2014. Request a copy or view PDF today.

divider line

New Products in this Area

GSK 137647

Potent and selective FFA4 (GPR120) agonist

AH 7614

Selective FFA4 (GPR120) antagonist

Prosaptide TX14(A)

Potent GPR37 and GPR37L1 agonist

AS 2034178

Selective FFA1 (GPR40) agonist

(±)-NBI 74330

Potent and selective CXCR3 antagonist

Purmorphamine

Smo receptor agonist

CTCE 9908

CXCR4 antagonist; antitumor

VUF 11207 fumarate

Potent CXCR7 agonist

TC-G 1006

Potent and selective sphingosine-1-phosphate receptor 1 (S1P1) agonist

Sign-up for new product e-alerts
divider line

Twitter Updates

Follow @Tocris on Twitter

Follow us on Twitter!

Tocris is now actively tweeting. For regular updates on news, events and special offers, follow @Tocris on Twitter.